Biogen Idec Receives Notificati?on of PDUFA Date Extension for Plegridy (Peginterf?eron Beta-1a)

Biogen Idec has announced that FDA has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for marketing approval of PLEGRIDY, a subcutaneous pegylated interferon candidate for relapsing forms of multiple sclerosis (RMS). The PDUFA date has been extended by 3 months, which is the standard extension period.

FDA has indicated that the extension of the PDUFA date is required to allow additional time for review of the application. The agency has not asked for additional studies.

About PLEGRIDY

PLEGRIDY is a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. PLEGRIDY is a member of the interferon class of treatments, which is often used as a first-line treatment for MS.

Regulatory authorities in the US and the European Union accepted the marketing applications for the review of PLEGRIDY in RMS in 2013.